Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 6/7/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Martin Schlumberger?

Martin J. Schlumberger

Director, Nuclear Medicine and Endocrine Tumors Division

Institut Gustave Roussy

Email: m***@***.fr

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Institut Gustave Roussy

Villejuif, �le-de-France,

France

Background Information

Employment History

Medullary Specialist

Service de Médecine Nucléaire


Affiliations

Thyroid Cancer Alliance

Board Member


Education

M.D.


M.D.

University of Paris - Sud


Web References(41 Total References)


Authors - Thyroid Disease ManagerThyroid Disease Manager

www.thyroidmanager.org [cached]

Martin Schlumberger , MD
Professor of Oncology, University of Paris-Sud, Director, Nuclear Medicine and Endocrine Tumors Division, Institut Gustave-Roussy, Villejuif, Paris, France.


EORTC phase II trial opens for patients with differentiated or medullary thyroid cancer progressing after first line therapy | EORTC

www.eortc.org [cached]

Dr. Martin Schlumberger of the Institut Gustave Roussy in Villejuif, France, and Coordinator of this study says, "This is a randomized phase II trial that evaluates the role of nintedanib, a potentially active drug, as second/third line treatment in patients with both differentiated and medullary thyroid cancer.


World Congress on Thyroid Cancer » » Keynote Presentations

thyroidworldcongress.com [cached]

Prof. Martin Schlumberger, Institut Gustav-Roussy, Villjuif, France


Authors - Thyroid Disease ManagerThyroid Disease Manager

www.thyroidmanager.org [cached]

Martin Schlumberger , MD
Professor of Oncology, University of Paris-Sud, Director, Nuclear Medicine and Endocrine Tumors Division, Institut Gustave-Roussy, Villejuif, Paris, France.


www.pharmacy-life.co.uk

'Lenvatinib represents a paradigm shift in the treatment of advanced thyroid cancer, and will bring new options to patients and clinicians,' said Martin Schlumberger, primary investigator and Professor of Oncology at the Institut Gustave Roussy, University Paris Sud. 'Clinicians will be excited to prescribe a treatment with significant benefits in progression-free survival.'


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory